Myeloid cell–specific loss of NPC1 in mice recapitulates microgliosis and neurodegeneration in patients with Niemann-Pick type C disease
Lina Dinkel,Selina Hummel,Valerio Zenatti,Mariagiovanna Malara,Yannik Tillmann,Alessio Colombo,Laura Sebastian Monasor,Jung H. Suh,Todd Logan,Stefan Roth,Lars Paeger,Patricia Hoffelner,Oliver Bludau,Andree Schmidt,Stephan A. Müller,Martina Schifferer,Brigitte Nuscher,Jasenka Rudan Njavro,Matthias Prestel,Laura M. Bartos,Karin Wind-Mark,Luna Slemann,Leonie Hoermann,Sebastian T. Kunte,Johannes Gnörich,Simon Lindner,Mikael Simons,Jochen Herms,Dominik Paquet,Stefan F. Lichtenthaler,Peter Bartenstein,Nicolai Franzmeier,Arthur Liesz,Antje Grosche,Tatiana Bremova-Ertl,Claudia Catarino,Skadi Beblo,Caroline Bergner,Susanne A. Schneider,Michael Strupp,Gilbert Di Paolo,Matthias Brendel,Sabina Tahirovic
DOI: https://doi.org/10.1126/scitranslmed.adl4616
IF: 17.1
2024-12-06
Science Translational Medicine
Abstract:Niemann-Pick type C (NPC) disease is an inherited lysosomal storage disorder mainly driven by mutations in the NPC1 gene, causing lipid accumulation within late endosomes/lysosomes and resulting in progressive neurodegeneration. Although microglial activation precedes neuronal loss, it remains elusive whether loss of the membrane protein NPC1 in microglia actively contributes to NPC pathology. In a mouse model with depletion of NPC1 in myeloid cells, we report severe alterations in microglial lipidomic profiles, including the enrichment of bis(monoacylglycero)phosphate, increased cholesterol, and a decrease in cholesteryl esters. Lipid dyshomeostasis was associated with microglial hyperactivity, marked by an increase in translocator protein 18 kDa (TSPO). These hyperactive microglia initiated a pathological cascade resembling NPC-like phenotypes, including a shortened life span, motor impairments, astrogliosis, neuroaxonal pathology, and increased neurofilament light chain (NF-L), a neuronal injury biomarker. As observed in the mouse model, patients with NPC showed increased NF-L in the blood and microglial hyperactivity, as visualized by TSPO-PET imaging. Reduced TSPO expression in blood-derived macrophages of patients with NPC was measured after N -acetyl- l -leucine treatment, which has been recently shown to have beneficial effects in patients with NPC, suggesting that TSPO is a potential marker to monitor therapeutic interventions for NPC. Conclusively, these results demonstrate that myeloid dysfunction, driven by the loss of NPC1, contributes to NPC disease and should be further investigated for therapeutic targeting and disease monitoring.
cell biology,medicine, research & experimental